Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody.

Stroh M, Sagert J, Burke JM, Apgar JF, Lin L, Millard BL, Kavanaugh WM.

CPT Pharmacometrics Syst Pharmacol. 2019 Jun 28. doi: 10.1002/psp4.12448. [Epub ahead of print]

2.

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

Tolcher AW, Papadopoulos KP, Patnaik A, Wilson K, Thayer S, Zanghi J, Gemo AT, Kavanaugh WM, Keer HN, LoRusso PM.

Ann Oncol. 2016 Mar;27(3):526-32. doi: 10.1093/annonc/mdv591. Epub 2015 Dec 8.

PMID:
26646757
3.

In vivo imaging of protease activity by Probody therapeutic activation.

Wong KR, Menendez E, Craik CS, Kavanaugh WM, Vasiljeva O.

Biochimie. 2016 Mar;122:62-7. doi: 10.1016/j.biochi.2015.11.003. Epub 2015 Nov 4.

4.

Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome.

Zhang H, Pao LI, Zhou A, Brace AD, Halenbeck R, Hsu AW, Bray TL, Hestir K, Bosch E, Lee E, Wang G, Liu H, Wong BR, Kavanaugh WM, Williams LT.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15741-5. doi: 10.1073/pnas.1412009111. Epub 2014 Oct 20.

5.

Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.

Harding TC, Long L, Palencia S, Zhang H, Sadra A, Hestir K, Patil N, Levin A, Hsu AW, Charych D, Brennan T, Zanghi J, Halenbeck R, Marshall SA, Qin M, Doberstein SK, Hollenbaugh D, Kavanaugh WM, Williams LT, Baker KP.

Sci Transl Med. 2013 Mar 27;5(178):178ra39. doi: 10.1126/scitranslmed.3005414.

6.

Semirational design of a potent, artificial agonist of fibroblast growth factor receptors.

Ballinger MD, Shyamala V, Forrest LD, Deuter-Reinhard M, Doyle LV, Wang JX, Panganiban-Lustan L, Stratton JR, Apell G, Winter JA, Doyle MV, Rosenberg S, Kavanaugh WM.

Nat Biotechnol. 1999 Dec;17(12):1199-204.

PMID:
10585718
7.
8.

An SH2 domain-containing 5' inositolphosphatase inhibits insulin-induced GLUT4 translocation and growth factor-induced actin filament rearrangement.

Vollenweider P, Clodi M, Martin SS, Imamura T, Kavanaugh WM, Olefsky JM.

Mol Cell Biol. 1999 Feb;19(2):1081-91.

9.

High-throughput screening for ligand-induced c-fos mRNA expression by branched DNA assay in Chinese hamster ovary cells.

Shyamala V, Khoja H, Anderson ML, Wang JX, Cen H, Kavanaugh WM.

Anal Biochem. 1999 Jan 1;266(1):140-7.

PMID:
9887223
10.

Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation.

Klippel A, Escobedo MA, Wachowicz MS, Apell G, Brown TW, Giedlin MA, Kavanaugh WM, Williams LT.

Mol Cell Biol. 1998 Oct;18(10):5699-711.

11.

3-Phosphohistidine cannot replace phosphotyrosine in high-affinity binding to phosphotyrosine binding or Src homology 2 domains.

Senderowicz L, Wang JX, Wang LY, Yoshizawa S, Kavanaugh WM, Turck CW.

Biochemistry. 1997 Aug 26;36(34):10538-44.

PMID:
9265634
12.

SIP/SHIP inhibits Xenopus oocyte maturation induced by insulin and phosphatidylinositol 3-kinase.

Deuter-Reinhard M, Apell G, Pot D, Klippel A, Williams LT, Kavanaugh WM.

Mol Cell Biol. 1997 May;17(5):2559-65.

13.
14.

Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways.

Klippel A, Reinhard C, Kavanaugh WM, Apell G, Escobedo MA, Williams LT.

Mol Cell Biol. 1996 Aug;16(8):4117-27.

15.

Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2.

Kavanaugh WM, Pot DA, Chin SM, Deuter-Reinhard M, Jefferson AB, Norris FA, Masiarz FR, Cousens LS, Majerus PW, Williams LT.

Curr Biol. 1996 Apr 1;6(4):438-45.

17.

PTB domain binding to signaling proteins through a sequence motif containing phosphotyrosine.

Kavanaugh WM, Turck CW, Williams LT.

Science. 1995 May 26;268(5214):1177-9.

PMID:
7539155
18.

An alternative to SH2 domains for binding tyrosine-phosphorylated proteins.

Kavanaugh WM, Williams LT.

Science. 1994 Dec 16;266(5192):1862-5.

PMID:
7527937
19.

Tyrosine 508 of the 85-kilodalton subunit of phosphatidylinositol 3-kinase is phosphorylated by the platelet-derived growth factor receptor.

Kavanaugh WM, Turck CW, Klippel A, Williams LT.

Biochemistry. 1994 Sep 13;33(36):11046-50.

PMID:
8086421
20.
21.

cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor.

Escobedo JA, Navankasattusas S, Kavanaugh WM, Milfay D, Fried VA, Williams LT.

Cell. 1991 Apr 5;65(1):75-82.

PMID:
1849460
22.
23.

Cyclic AMP blocks expression of the c-sis gene in tumor cells.

Harsh GR, Kavanaugh WM, Starksen NF, Williams LT.

Oncogene Res. 1989;4(1):65-73.

PMID:
2541392
24.

Serotonin-induced deoxyribonucleic acid synthesis in vascular smooth muscle cells involves a novel, pertussis toxin-sensitive pathway.

Kavanaugh WM, Williams LT, Ives HE, Coughlin SR.

Mol Endocrinol. 1988 Jul;2(7):599-605.

PMID:
2842665
25.

Transcriptional regulation of the A and B chain genes of platelet-derived growth factor in microvascular endothelial cells.

Kavanaugh WM, Harsh GR 4th, Starksen NF, Rocco CM, Williams LT.

J Biol Chem. 1988 Jun 15;263(17):8470-2.

26.

Sequence homologies between A subunits of Escherichia coli and Vibrio cholerae enterotoxins.

Spicer EK, Kavanaugh WM, Dallas WS, Falkow S, Konigsberg WH, Schafer DE.

Proc Natl Acad Sci U S A. 1981 Jan;78(1):50-4.

Supplemental Content

Loading ...
Support Center